Aktuellt
SENASTE
The critical focus for Ascelia is now to advance the pivotal Mangoral (Orviglance) study and initiate the phase 2 study to Oncoral (daily irinotecan chemotherapy). Ascelia is in the process of increasing the number of sites and patients for the US (SPARKLE) Mangoral study to meet the goal of complete patient recruitment in H1 2022. Ascelia is also repeating the ambition to initiate the phase 2 Oncoral study during this present quarter which is reassuring.
LÄS MER
